Biosimilars Report On Biologics and Biosimilars Market in the United States Released This Week

This week, IQVIA released an independent report on its research into the current state of the biologics market in the United States. IQVIA, formerly Quintiles and IMS Health, Inc., is a contract research organization serving the combined industries of health information technology and clinical research. In an overview of the biosimilars market, IQVIA reports that “[d]evelopment and approvals of biosimilars have been accelerating, with 33 approvals across 13 molecules to date,” with “[l]arge pharma companies . . . dominat[ing] the marketing of biosimilars” and “[t]he 22 launched biosimilars [sharing a] 20% volume share of the accessible market.”  IQVIA highlights bevacizumab, trastuzumab, and rituximab as recent biosimilar launches “set to reach nearly 60% volume share by the end of their second year on the market,” which, IQVIA notes, is “significantly higher and faster than prior biosimilars. . . and similar to the high rates of adoption in Europe.”